Showing 6121-6130 of 8554 results for "".
- Laura Bush Named SDPA’s Board Presidenthttps://practicaldermatology.com/news/laura-bush-named-sdpas-board-president/2461847/Georgia-based dermatology physician assistant Laura Bush is the new president of the Society of Dermatology Physician Assistant's (SDPA) Board of Directors. Bush, a DermPA with Fayette Area Dermatology in Fayetteville, Georgia, will serve a one-year term leading the nine-membe
- WCD News: Janssen's Oral IL-23 Blocker Shows Promise in Phase 2b PsO Studyhttps://practicaldermatology.com/news/wcd-news/2461839/Janssen’s novel oral interleukin-23 receptor (IL-23R) antagonist peptide JNJ-2113 performed well in the Phase 2b FRONTIER 1 clinical trial of adults with moderate-to-severe plaque psoriasis (PsO), the Company reports. JNJ-2113 is a novel oral IL-23R antagonist peptide that binds w
- Biosimilar News: Coherus Launches Humira Biosimilar at $995 per Carton in U.S.https://practicaldermatology.com/news/biosimilar-news-coherus-launches-humira-biosimilar-at-995-per-carton-in-us/2461834/Coherus BioSciences, Inc’s YUSIMRY (adalimumab-aqvh) is now available for commercial sale in the United States at a list price of $995 per carton for two 40 mg/0.8 mL autoinjectors. This cost represents a discount of more than 85% to Humira (adalimumab), currently price
- WCD News: Experts Excited About Ornovi’s Next Generation JAK Inhibitorhttps://practicaldermatology.com/news/wcd-news-experts-excited-about-ornovis-next-generation-jak-inhibitor/2461833/Ornovi's OR-101 is a highly selective next generation JAK3-ITK inhibitor with potentially a better safety profile than JAK inhibitors currently on the market, according to a presentation at the 25th World Congress of Dermatology Meeting 2023 in Singapore. Seemal Desa
- Biosimilar News: Sandoz Launches Humira Biosimilar Hyrimoz in the U.S.https://practicaldermatology.com/news/biosimilar-news-sandoz-launches-humira-biosimilar-hyrimoz-in-the-us/2461832/Sandoz’s a citrate-free high-concentration formulation of its biosimilar Hyrimoz (adalimumab-adaz) injection is now available in the U.S. Hyrimoz HCF (100 mg/mL) is approved to treat all indications no longer covered by the regulatory exclusivity for the reference medicine, H
- Biosimilar Update: Humira Biosimilar Cyltezo Now Available in U.S.https://practicaldermatology.com/news/biosimilar-update-humira-biosimilar-cyltezo-now-available-in-us/2461831/Boehringer Ingelheim’s Cyltezo (adalimumab-adbm), a U.S. Food and Drug Administration (FDA)-approved Interchangeable biosimilar to Humira (adalimumab), is now commercially available in the U.S. Cyltezo was initially approved as a biosimilar in 2017 for use in multi
- TikTok Trend Watch: Browning Lotions and Summer Tanshttps://practicaldermatology.com/news/tik-tok-trend-watch-browning-lotions-and-summer-tans/2461830/Skinfluencers on social media are praising browning lotions for perfecting their summer tans. What is browning lotion? Browning lotion or tanning accelerators work with the sun's UV rays to darken your skin faster. What could go wrong?
- Dermatology Around the Globe: First JAK for AD Approved in Indiahttps://practicaldermatology.com/news/dermatology-around-the-globe-first-jak-for-ad-approved-in-india/2461828/Intas Pharmaceuticals Ltd launched TOFATAS –a Drugs Controller General of India (DCGI) -approved, Tofacitinib Ointment 2% w/w for the treatment of mild to moderate Atopic Dermatitis (AD) in patients 18 years and above experiencing flare-ups of the disease. "The
- Open Enrollment Underway for Phase 2b Trial of Topical AMTX-100 CF3 in ADhttps://practicaldermatology.com/news/open-enrollment-underway-for-phase-2b-trial-of-topical-amtx-100-cf3-in-ad/2461827/Amytrx Therapeutics is enrolling mild to moderate atopic dermatitis patients for its Phase 2b clinical trial of a topical formulation of AMTX-100 CF3. Eligible adults interested in participating or learning more about the trial are encouraged to visit the
- Fifth Piece of Art Added to Boehringer Ingelheim, FIT's DTech Unwearable Collectionhttps://practicaldermatology.com/news/fifth-piece-of-art-added-to-boehringer-ingelheim-fits-dtech-unwearable-collection/2461825/In partnership with the Fashion Institute of Technology's (FIT) DTech Lab and world-renowned designer, Bart Hess, Boehringer Ingelheim is introducing a fifth piece to The Unwearable Collection, an art collection that uses raw materials like paper and glass to uniquely illustrat